Danish Study Finds No Tylenol-Autism Link, But Kenvue's Regulatory Overhang Remains

What happened

A nationwide Danish study published on April 13, 2026, found no association between Tylenol use during pregnancy and autism in children, countering previous concerns that have fueled regulatory scrutiny. The DeepValue master report highlights that Kenvue faces significant risk from FDA-initiated acetaminophen pregnancy labeling actions since September 2025, which the company warns could depress sales and increase litigation risk. This new study may provide Kenvue with scientific support to resist labeling changes, potentially easing near-term investor anxiety. However, critically, the FDA's regulatory process is multifaceted and unlikely to be resolved by a single study, and Kenvue's filings explicitly state that ongoing actions could still harm demand. Moreover, the Skin Health & Beauty segment remains vulnerable with a thin fair-value cushion, ensuring that the overall investment thesis of event-driven downside catalysts persists.

Implication

In the short term, the stock may see a relief rally as headline risk around Tylenol diminishes, but this should be tempered by the need to monitor the FDA's response, which could still advance labeling changes. Over the medium term, the Kimberly-Clark acquisition timeline and foreign approvals remain pivotal, with the deal providing a merger-arbitrage floor but subject to regulatory uncertainty. The study does not address the Skin Health & Beauty segment's impairment risk, where a narrow fair-value cushion and prior $488 million impairment signal ongoing challenges. Additionally, Kenvue's high valuation multiples and restructuring charges leave little margin for error if sales trends weaken or cash flow is impacted. Ultimately, while the news is favorable, it does not justify shifting from the 'POTENTIAL SELL' rating without evidence of sustained demand stability and regulatory resolution.

Thesis delta

The Danish study slightly reduces the probability of the bear case where FDA advances adverse acetaminophen labeling, but the core investment thesis remains unchanged. Investors should still prioritize monitoring foreign deal approvals and FDA actions over the next 6-12 months, as the stock's valuation assumes a stable earnings stream that is not yet assured by this single development.